MERCK & Co is believed to have
joined the race to purchase US
cancer drugmaker Medivation,
alongside expressions of interest
from Sanofi, Pfizer, Celgene and
Gilead, Reuters is reporting.
Medivation products include
Xtandi (enzalutamide) which is PBS listed
for the treatment of prostate
cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Aug 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.